Douglas Roeder Acquires 22,686 Shares of Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) Stock

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) Director Douglas Roeder bought 22,686 shares of the stock in a transaction dated Tuesday, May 12th. The stock was acquired at an average price of $5.56 per share, with a total value of $126,134.16. Following the completion of the purchase, the director owned 144,635 shares of the company’s stock, valued at $804,170.60. This represents a 18.60% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Senseonics Holdings, Inc. Common Stock Price Performance

Shares of NASDAQ:SENS traded down $0.26 during midday trading on Wednesday, reaching $5.50. The company’s stock had a trading volume of 563,767 shares, compared to its average volume of 637,784. Senseonics Holdings, Inc. Common Stock has a fifty-two week low of $4.79 and a fifty-two week high of $12.58. The company has a market capitalization of $229.90 million, a P/E ratio of -2.75 and a beta of 1.05. The company has a quick ratio of 4.55, a current ratio of 3.51 and a debt-to-equity ratio of 1.05. The stock’s fifty day simple moving average is $6.47.

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) last announced its earnings results on Thursday, May 7th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.06). Senseonics Holdings, Inc. Common Stock had a negative net margin of 213.87% and a negative return on equity of 129.97%. The business had revenue of $11.71 million during the quarter. On average, analysts forecast that Senseonics Holdings, Inc. Common Stock will post -2.7 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

SENS has been the subject of a number of research reports. Weiss Ratings initiated coverage on Senseonics Holdings, Inc. Common Stock in a research note on Tuesday, February 17th. They issued a “sell (d-)” rating for the company. HC Wainwright lowered their price objective on Senseonics Holdings, Inc. Common Stock from $18.50 to $14.00 and set a “buy” rating for the company in a research report on Tuesday. Finally, Stifel Nicolaus cut their target price on shares of Senseonics Holdings, Inc. Common Stock from $9.00 to $8.00 and set a “hold” rating on the stock in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $17.00.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of SENS. Ausdal Financial Partners Inc. boosted its stake in shares of Senseonics Holdings, Inc. Common Stock by 50.0% in the 3rd quarter. Ausdal Financial Partners Inc. now owns 105,000 shares of the company’s stock valued at $46,000 after purchasing an additional 35,000 shares during the last quarter. Townsend Asset Management Corp NC ADV acquired a new position in shares of Senseonics Holdings, Inc. Common Stock during the 4th quarter worth about $60,000. GSK plc acquired a new position in shares of Senseonics Holdings, Inc. Common Stock during the 4th quarter worth about $60,000. Kestra Advisory Services LLC bought a new stake in shares of Senseonics Holdings, Inc. Common Stock in the 1st quarter valued at about $68,000. Finally, Sanctuary Advisors LLC bought a new stake in shares of Senseonics Holdings, Inc. Common Stock in the 4th quarter valued at about $71,000. Institutional investors own 12.36% of the company’s stock.

About Senseonics Holdings, Inc. Common Stock

Senseonics Holdings, Inc develops and commercializes long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company’s primary product family is the Eversense system, which combines a small subcutaneously implanted sensor, a removable external transmitter, and companion smartphone applications to provide continuous glucose readings and alerts. Senseonics positions its technology as an alternative to wearable patch-style CGMs by offering multi-month sensor longevity and on-body vibration alerts delivered through the transmitter.

Senseonics supports clinical and commercial activities that include research and development, regulatory engagement, manufacturing and distribution, and training for healthcare providers who perform sensor insertion and removal.